Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)

INTRODUCTION: Despite the development of new therapies for advanced prostate cancer, it remains the most common cause of cancer and the second leading cause of cancer death in men. It is critical to develop novel agents for the treatment of prostate cancer, particularly those that target aspects of...

Descripción completa

Detalles Bibliográficos
Autores principales: Scheinberg, Tahlia, Kench, James, Stockler, Martin, Mahon, Kate L, Sebastian, Lucille, Stricker, Phillip, Joshua, Anthony M, Woo, H, Thanigasalam, Ruban, Ahmadi, Nariman, Centenera, Margaret M, Butler, Lisa M, Horvath, Lisa G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045211/
https://www.ncbi.nlm.nih.gov/pubmed/31988233
http://dx.doi.org/10.1136/bmjopen-2019-033667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7045211/
https://www.ncbi.nlm.nih.gov/pubmed/31988233
http://dx.doi.org/10.1136/bmjopen-2019-033667

Ejemplares similares